The role of real-world data in advancement of Alzheimer’s treatments
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that...
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that...
RWE and HEOR teams face increasing pressure to produce evidence that holds up beyond internal...
Thank you for visiting HealthVerity at Fierce 2025 HealthVerity had a fantastic week at Fierce...
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
Thank you to everyone who joined us at ISPOR 2025 in Montreal. Whether you stopped by our booth,...
Key benefits of real-world lab data for life sciences and pharma Real-world lab results enhance...
Background of the CRWDi project While the COVID-19 pandemic is behind us, the virus remains a...
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that gradually erodes memory and cognitive function, affecting patients and their families long before the disease reaches its final stages.¹ As the population...